placebo in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results COVID-PEP-Post exposure (Boulware), 2020 (REV) 1.02 [0.02; 51.39]
PATCH-cohort 3 PreP (Abella), 2020 (REV) 1.00 [0.02; 51.16]
1.01 [0.06 ; 16.22 ] COVID-PEP-Post exposure (Boulware), 2020 (REV), PATCH-cohort 3 PreP (Abella), 2020 (REV) 2 0% 953 low not evaluable hospitalizationdetailed results COVID-PEP-Post exposure (Boulware), 2020 (REV) 1.02 [0.06; 16.32]
Rojas-Serrano, 2021 (REV) 0.95 [0.02; 48.81]
1.00 [0.10 ; 9.62 ] COVID-PEP-Post exposure (Boulware), 2020 (REV), Rojas-Serrano, 2021 (REV) 2 0% 948 low not evaluable symptomatic Covid-19detailed results Barnabas RV, 2020 (REV) 0.79 [0.49; 1.26]
COVID PREP (HCQ 1x week, Rajasingham), 2020 (REV) 1.54 [0.43; 5.52]
COVID PREP HCQ (2x week, Rajasingham), 2020 (REV) 0.85 [0.29; 2.51]
COVID-PEP-Post exposure (Boulware), 2020 (REV) 1.19 [0.79; 1.80]
HERO-HCQ (Naggie), 2021 (REV) 1.33 [0.87; 2.03]
Rojas-Serrano, 2021 (REV) 6.20 [0.72; 53.10]
1.13 [0.86 ; 1.48 ] Barnabas RV, 2020 (REV), COVID PREP (HCQ 1x week, Rajasingham), 2020 (REV), COVID PREP HCQ (2x week, Rajasingham), 2020 (REV), COVID-PEP-Post exposure (Boulware), 2020 (REV), HERO-HCQ (Naggie), 2021 (REV), Rojas-Serrano, 2021 (REV) 6 14% 5,113 low not evaluable asymptomatic COVID casedetailed results EPICOS (Polo), 2022 (REV) 1.04 [0.53; 2.05]
1.04 [0.53 ; 2.05 ] EPICOS (Polo), 2022 (REV) 1 0% 454 NA not evaluable infection (PCR positive symptomatic or not)detailed results Barnabas RV, 2020 (REV) 0.91 [0.60; 1.37]
COVID PREP (HCQ 1x week, Rajasingham), 2020 (REV) 1.37 [0.84; 2.23]
COVID PREP HCQ (2x week, Rajasingham), 2020 (REV) 1.35 [0.83; 2.21]
COVID-PEP-Post exposure (Boulware), 2020 (REV) 0.83 [0.34; 2.02]
EPICOS (Polo), 2022 (REV) 1.15 [0.62; 2.14]
HERO-HCQ (Naggie), 2021 (REV) 1.33 [0.87; 2.03]
PATCH-cohort 3 PreP (Abella), 2020 (REV) 1.05 [0.25; 4.41]
Rojas-Serrano, 2021 (REV) 6.20 [0.72; 53.10]
1.19 [0.97 ; 1.45 ] Barnabas RV, 2020 (REV), COVID PREP (HCQ 1x week, Rajasingham), 2020 (REV), COVID PREP HCQ (2x week, Rajasingham), 2020 (REV), COVID-PEP-Post exposure (Boulware), 2020 (REV), EPICOS (Polo), 2022 (REV), HERO-HCQ (Naggie), 2021 (REV), PATCH-cohort 3 PreP (Abella), 2020 (REV), Rojas-Serrano, 2021 (REV) 8 0% 5,692 low not evaluable serious adverse eventsdetailed results Barnabas RV, 2020 (REV) 0.96 [0.14; 6.88]
PATCH-cohort 3 PreP (Abella), 2020 (REV) 1.00 [0.02; 51.16]
0.97 [0.17 ; 5.63 ] Barnabas RV, 2020 (REV), PATCH-cohort 3 PreP (Abella), 2020 (REV) 2 0% 961 low not evaluable adverse eventsdetailed results Barnabas RV, 2020 (REV) 0.63 [0.42; 0.95]
COVID PREP (HCQ 1x week, Rajasingham), 2020 (REV) 1.69 [1.26; 2.26]
COVID PREP HCQ (2x week, Rajasingham), 2020 (REV) 0.49 [0.37; 0.66]
COVID-PEP-Post exposure (Boulware), 2020 (REV) 0.30 [0.21; 0.43]
Rojas-Serrano, 2021 (REV) 0.61 [0.29; 1.28]
0.63 [0.33 ; 1.21 ] Barnabas RV, 2020 (REV), COVID PREP (HCQ 1x week, Rajasingham), 2020 (REV), COVID PREP HCQ (2x week, Rajasingham), 2020 (REV), COVID-PEP-Post exposure (Boulware), 2020 (REV), Rojas-Serrano, 2021 (REV) 5 94% 3,633 low not evaluable 0.2 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-23 07:08 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
